NIERENBERG DAVID Form SC 13D/A September 30, 2004

Securities and Exchange Commission Washington, D.C. 20549

Schedule 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4) *

Natus Medical Incorporated (BABY) (Name of Issuer)

Common (Title of Class of Securities)

639050103 (CUSIP Number)

David Nierenberg The D3 Family Fund 19605 NE 8th Street Camas, WA 98607 360-604-8600

Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following

1	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON			
	The D3 Family Fund, L.P. (David Nierenberg is president of Partner, which is Nierenberg Investment Management Company		General	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*			
		(a)	X	
		(b)	_	
3	SEC USE ONLY			
4	SOURCE OF FUNDS*			
	WC			
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)		1_1	

6	CITIZENSH	IP OF	R PLACE OF ORGANIZATION			
	Washingto	n 				
		7	SOLE VOTING POWER			
			1,269,472 common shares (7.4%)			
		8	SHARED VOTING POWER			
BENE	SHARES EFICIALLY		0			
OV	WNED BY EACH	9	SOLE DISPOSITIVE POWER			
	EPORTING PERSON		1,269,472			
	WITH	10	SHARED DISPOSITIVE POWER			
			0			
11	AGGREGATE	AMOU	NT BENEFICIALLY OWNED BY EACH REPORTING PERSO)N		
	2,280,024	shar	res (13.4%)			
12	 CHECK BOX	 IF T	HE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERT	: 'AIN S'	 HARES*	 _
 13	PERCENT O	 F CLA	ASS REPRESENTED BY AMOUNT IN ROW (11)			
	13.4%					
14	TYPE OF R	 EPORT				
	PN					
			*SEE INSTRUCTIONS BEFORE FILLING OUT!			
1			ING PERSON IDENTIFICATION NOS. OF ABOVE PERSON			
			Retirement Fund, L.P. (David Nierenberg is pr	asida:	nt of	+ h_
			er, which is Nierenberg Investment Management			
2	CHECK THE	APPF	COPRIATE BOX IF A MEMBER OF A GROUP*	(2)	IVI	
				(a) (b)		
3	SEC USE O	NLY				
4	SOURCE OF	FUND	 S*			
	WC					
5			ISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED			
	PURSUANT	TO II	'EMS 2(d) OR 2(e)		1_1	

6	CITIZENSH	 IP OR	PLACE OF ORGANIZATION		
	Washington	n			
		7	SOLE VOTING POWER		
			396,950 common shares (203%)		
	JMBER OF SHARES	8	SHARED VOTING POWER		
BENE	EFICIALLY NNED BY		0		
	EACH EPORTING	9	SOLE DISPOSITIVE POWER		
	PERSON WITH		396,950		
	W1111	10	SHARED DISPOSITIVE POWER		
			0		
11	AGGREGATE	AMOU	NT BENEFICIALLY OWNED BY EACH REPORTING PERSO	ON	
	2,280,024	shar	es (13.4%)		
12	12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* _				_
13	PERCENT O	F CLA	SS REPRESENTED BY AMOUNT IN ROW (11)		
	13.4%				
14	TYPE OF R	EPORT	ING PERSON*		
	PN				
			*SEE INSTRUCTIONS BEFORE FILLING OUT!		
1			ING PERSON IDENTIFICATION NOS. OF ABOVE PERSON		
			Bulldog Fund, L.P. (David Nierenberg is presi r, which is Nierenberg Investment Management		
2	CHECK THE	APPR	OPRIATE BOX IF A MEMBER OF A GROUP*	(a) X (b) _	
3	SEC USE O	NLY			
4	SOURCE OF	FUND	S*		
	WC				

5			TEMS 2(d) OR 2(e)		1_1	
6	CITIZENSH	IIP OF	R PLACE OF ORGANIZATION			
	Washingto	n				
		7	SOLE VOTING POWER			
			268,233 common shares (1.6%)			
	UMBER OF	8	SHARED VOTING POWER			
BENI	EFICIALLY		0			
	WNED BY EACH	9	SOLE DISPOSITIVE POWER			
	EPORTING PERSON		268,233			
	WITH	10	SHARED DISPOSITIVE POWER			
			0			
11	AGGREGATE	JOMA 2	JNT BENEFICIALLY OWNED BY EACH REPORTING PERSO	ON		
	2,280,024	shar	res (13.4%)			
12	CHECK BOX	 (IF 1	THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CER			_
13	PERCENT C	F CL	ASS REPRESENTED BY AMOUNT IN ROW (11)			
	13.4%					
14	TYPE OF R	REPORT	TING PERSON*			
	PN					
			*SEE INSTRUCTIONS BEFORE FILLING OUT!			
1			TING PERSON . IDENTIFICATION NOS. OF ABOVE PERSON			
			en's Fund, L.P. (David Nierenberg is president		the Gene	eral
2	CHECK THE	APPF	ROPRIATE BOX IF A MEMBER OF A GROUP*		X _	
3	SEC USE C					
	SOUDCE OF	י ביווער				

	WC				
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) _				
6	CITIZENSH	IP OR	PLACE OF ORGANIZATION		
	Washingto	n 			
		7	SOLE VOTING POWER		
			86,811 common shares (0.5%)		
	MBER OF HARES	8	SHARED VOTING POWER		
BENE	FICIALLY NED BY		0		
	EACH PORTING	9	SOLE DISPOSITIVE POWER		
P	ERSON WITH		86,811		
	AA T T I I	10	SHARED DISPOSITIVE POWER		
			0		
11	AGGREGATE	AMOU	NT BENEFICIALLY OWNED BY EACH REPORTING PERSO	N	
	2,280,024 shares (13.4%)				
12	CHECK BOX	IF T	THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERT	AIN SI	HARES* _
13	PERCENT O	F CLA	SS REPRESENTED BY AMOUNT IN ROW (11)		
	13.4%				
14	TYPE OF R	EPORT	ING PERSON*		
	PN				
			*SEE INSTRUCTIONS BEFORE FILLING OUT!		
1			ING PERSON IDENTIFICATION NOS. OF ABOVE PERSON		
			e Fund, L.P. (David Nierenberg is president of is Nierenberg Investment Management Company.		General
2	CHECK THE	APPR	OPRIATE BOX IF A MEMBER OF A GROUP*	(a) (b)	
3					

4	SOURCE OF FUNDS*				
	WC				
5			DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED TEMS 2(d) OR 2(e)	I_I	
6	CITIZENSH	IP O	R PLACE OF ORGANIZATION		
	Washingto	n			
		7	SOLE VOTING POWER		
			257,058 common shares (1.5%)		
	NUMBER OF		SHARED VOTING POWER		
BENE	SHARES CFICIALLY		0		
	OWNED BY EACH REPORTING PERSON WITH		SOLE DISPOSITIVE POWER		
P			257,058		
			SHARED DISPOSITIVE POWER		
			0		
11	AGGREGATE	AMO	UNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	2,280,024	sha	res (13.4%)		
12	CHECK BOX	IF T	THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAI	N SHARES* _	
13	PERCENT O	F CL	ASS REPRESENTED BY AMOUNT IN ROW (11)		
	13.4%				
14	TYPE OF R	EPOR	TING PERSON*		
	PN				
			*SEE INSTRUCTIONS BEFORE FILLING OUT!		
1			TING PERSON . IDENTIFICATION NOS. OF ABOVE PERSON		
	Henry Hoo	per			
2	CHECK THE	APPI		a) X b) _	
3	SEC USE O	NLY			

4	SOUR	CE OF	FUND	S*
	WC			
5				ISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED EMS 2(d) OR 2(e) _
6	CITI	ZENSH	IP OR	PLACE OF ORGANIZATION
	Unit	ed Sta	ates	of America
			7	SOLE VOTING POWER
				1,500 common shares (0.0%)
			8	SHARED VOTING POWER
BENE	HARES FICIA	LLY		0
OWNED BY EACH REPORTING PERSON WITH			9	SOLE DISPOSITIVE POWER
		1		1,500
			10	SHARED DISPOSITIVE POWER
				0
11	AGGR	EGATE	AMOU	NT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	2,28	0,024	shar	es (13.4%)
12	CHEC	K BOX	IF T	HE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* _
13	PERC	ENT O	 F CLA	SS REPRESENTED BY AMOUNT IN ROW (11)
	13.4	%		
14	TYPE	OF R	EPORT	ING PERSON*
	PN			
				*SEE INSTRUCTIONS BEFORE FILLING OUT!
Item	1.	Secur	ity a	nd Issuer.
				ck of Natus Medical Incorporated, 1501 Industrial Road, San 94070
Item	2.	Ident	ity a	nd Background.
		whose micro	prin -cap . No	cily Fund, L.P. is a Washington State limited partnership, cipal business is investing in the equities of public issuers. Located at 19605 N.E. 8th St., Camas, Washington convictions or administrative proceedings as described in 2).

Item 3. Source and Amount of Funds or Other Consideration.

Source of funds is money invested in the partnership by its partners.

Item 4. Purpose of Transaction.

We continue to be pleased with BABY's progress, so much so that we anticipate purchasing more shares right up to the poison pill limit of 15%, subject, of course, to price and availability.

BABY has strengthened corporate governance with the addition of three new outside directors and the election of a new independent board Chair, Bob Gunst. We have worked closely with Bob before, when he served as board chair at Garden Fresh Restaurant (LTUS), where he did an excellent job of building, and of harvesting, shareholder value.

Also, we are pleased with the actions Jim Hawkins already has taken during his first several months as BABY's new CEO. Not only is he cost-reducing the company to immediate profitability and flattening its previously top heavy management structure, more importantly, he is taking the steps needed to reinvigorate growth in BABY's core hearing screening business. The just-announced acquisition of the Fischer-Zoth company is far more significant than its current size: it should enable BABY to accelerate penetration of foreign country markets which prefer the OAE modality; it could build audiologist support for BABY; it brings strong technology capability to BABY's R&D department; and it opens up the adjacent market segment of office-based pediatrician screening of children. At his prior company Jim Hawkins did a terrific job of building synergistic, profitable growth through acquisitions. With Fischer-Zoth he is doing the same thing here at BABY.

Item 5. Interest in Securities of the Issuer.

(a,b) D3 Family Fund owns and has sole voting power over 1,269,472 BABY shares.

(C)	Date	Shares Bought	Price
	8/23/04	2,800	5.25
	9/22/04	30,000	6.54
	9/28/04	19,150	6.31
	9/29/04	433,350	6.64

- (d) N/A
- (e) N/A

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

N/A

Item 7. Material to be Filed as Exhibits.

N/A

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sept. 29, 2004

/s/ DAVID NIERENBERG

Date

David Nierenberg
President

Nierenberg Investment Management Company, Inc., the General Partner of The D3 Family Fund, L.P.

Item 1. Security and Issuer.

Common Stock of Natus Medical Incorporated, 1501 Industrial Road, San Carlos, CA 94070

Item 2. Identity and Background.

The D3 Family Retirement Fund, L.P. is a Washington State limited partnership, whose principal Business is investing in the equities of public micro-cap issuers. Located at 19605 N.E. 8th St., Camas, Washington 98607. No convictions or administrative proceedings as described in 2 (d) and (e).

Item 3. Source and Amount of Funds or Other Consideration.

Source of funds is money invested in the partnership by its partners.

Item 4. Purpose of Transaction.

We continue to be pleased with BABY's progress, so much so that we anticipate purchasing more shares right up to the poison pill limit of 15%, subject, of course, to price and availability.

BABY has strengthened corporate governance with the addition of three new outside directors and the election of a new independent board Chair, Bob Gunst. We have worked closely with Bob before, when he served as board chair at Garden Fresh Restaurant (LTUS), where he did an excellent job of building, and of harvesting, shareholder value.

Also, we are pleased with the actions Jim Hawkins already has taken during his first several months as BABY's new CEO. Not only is he cost-reducing the company to immediate profitability and flattening its previously top heavy management structure, more importantly, he is taking the steps needed to reinvigorate growth in BABY's core hearing screening business. The just-announced acquisition of the Fischer-Zoth company is far more significant than its current size: it should enable BABY to accelerate penetration of foreign country markets which prefer the OAE modality; it could build audiologist support for BABY; it brings strong technology capability to BABY's R&D department; and it opens up the adjacent market segment of office-based pediatrician screening of children. At his prior company Jim Hawkins did a terrific job of building synergistic, profitable growth through acquisitions. With Fischer-Zoth he is doing the same thing here at BABY.

- Item 5. Interest in Securities of the Issuer.
 - (a,b) The D3 Family Retirement Fund, L.P. owns and has sole voting power over 396,950 BABY shares
 - (c) Date Shares Bought Price

9/28/04 9/29/04	5,850 132,550	6.32 6.64
N/A		
N/A		

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

N/A

(d)

(e)

Item 7. Material to be Filed as Exhibits.

N/A

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sept. 29, 2004	/s/ DAVID NIERENBERG
Date	David Nierenberg
	President
	Nierenberg Investment Management
	Company, Inc., the General Partner
	of The D3 Family retirement Fund, L.P.

Item 1. Security and Issuer.

Common Stock of Natus Medical Incorporated, 1501 Industrial Road, San Carlos, CA 94070

Item 2. Identity and Background.

The D3 Children's Fund, L.P. is a Washington State limited partnership, whose principal business is investing in the equities of public micro-cap issuers. Located at 19605 N.E. 8th St., Camas, Washington 98607. No convictions or administrative proceedings as described in 2 (d) and (e).

Item 3. Source and Amount of Funds or Other Consideration.

Source of funds is money invested in the partnership by its partners.

Item 4. Purpose of Transaction.

We continue to be pleased with BABY's progress, so much so that we anticipate purchasing more shares right up to the poison pill limit of 15%, subject, of course, to price and availability.

BABY has strengthened corporate governance with the addition of three new outside directors and the election of a new independent board Chair, Bob Gunst. We have worked closely with Bob before, when he

served as board chair at Garden Fresh Restaurant (LTUS), where he did an excellent job of building, and of harvesting, shareholder value.

Also, we are pleased with the actions Jim Hawkins already has taken during his first several months as BABY's new CEO. Not only is he cost-reducing the company to immediate profitability and flattening its previously top heavy management structure, more importantly, he is taking the steps needed to reinvigorate growth in BABY's core hearing screening business. The just-announced acquisition of the Fischer-Zoth company is far more significant than its current size: it should enable BABY to accelerate penetration of foreign country markets which prefer the OAE modality; it could build audiologist support for BABY; it brings strong technology capability to BABY's R&D department; and it opens up the adjacent market segment of office-based pediatrician screening of children. At his prior company Jim Hawkins did a terrific job of building synergistic, profitable growth through acquisitions. With Fischer-Zoth he is doing the same thing here at BABY.

- Item 5. Interest in Securities of the Issuer.
 - (a,b) D3 Children's Fund, L.P. owns and has sole voting power over 86,811 BABY shares.

(C)	Date	Shares Bought	Price	
	9/29/04	22,000	6.64	

- (d) N/A
- (e) N/A

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

N/A

Item 7. Material to be Filed as Exhibits.

N/A

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sept. 29, 2004 /s/ DAVID NIERENBERG

Date David Nierenberg
President
Nierenberg Investment Management
Company, Inc., the General Partner
of The D3 Children's Fund, L.P.

Item 1. Security and Issuer.

Common Stock of Natus Medical Incorporated, 1501 Industrial Road, San Carlos, CA 94070

Item 2. Identity and Background.

The D3 Offshore Fund, L.P. is a Washington State limited partnership, whose principal business is investing in the equities of public micro-cap issuers. Located at 19605 N.E. 8th St., Camas, Washington 98607. No convictions or administrative proceedings as described in 2 (d) and (e).

Item 3. Source and Amount of Funds or Other Consideration.

Source of funds is money invested in the partnership by its partners.

Item 4. Purpose of Transaction.

We continue to be pleased with BABY's progress, so much so that we anticipate purchasing more shares right up to the poison pill limit of 15%, subject, of course, to price and availability.

BABY has strengthened corporate governance with the addition of three new outside directors and the election of a new independent board Chair, Bob Gunst. We have worked closely with Bob before, when he served as board chair at Garden Fresh Restaurant (LTUS), where he did an excellent job of building, and of harvesting, shareholder value.

Also, we are pleased with the actions Jim Hawkins already has taken during his first several months as BABY's new CEO. Not only is he cost-reducing the company to immediate profitability and flattening its previously top heavy management structure, more importantly, he is taking the steps needed to reinvigorate growth in BABY's core hearing screening business. The just-announced acquisition of the Fischer-Zoth company is far more significant than its current size: it should enable BABY to accelerate penetration of foreign country markets which prefer the OAE modality; it could build audiologist support for BABY; it brings strong technology capability to BABY's R&D department; and it opens up the adjacent market segment of office-based pediatrician screening of children. At his prior company Jim Hawkins did a terrific job of building synergistic, profitable growth through acquisitions. With Fischer-Zoth he is doing the same thing here at BABY.

Item 5. Interest in Securities of the Issuer.

(a,b) D3 Offshore Fund, L.P. owns and has sole voting power over 257,058 BABY shares.

(C)	Date	Shares Bought	Price
	9/02/04	2,952	5.55
	9/03/04	8,000	5.54
	9/15/04	10,000	6.75
	9/16/04	15,000	6.54
	9/17/04	48,000	6.53
	9/20/04	1,000	6.47
	9/29/04	56,900	6.64

- (d) N/A
- (e) N/A

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

N/A

Item 7. Material to be Filed as Exhibits.

N/A

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sept. 29, 2004

/s/ DAVID NIERENBERG

Date

David Nierenberg

President Nierenberg Investment Management

Company, Inc., the General Partner of The D3 Offshore Fund, L.P.

Item 1. Security and Issuer.

Common Stock of Natus Medical Incorporated, 1501 Industrial Road, San Carlos, CA 94070

Item 2. Identity and Background.

The D3 Family Bulldog Fund, L.P. is a Washington State limited partnership, whose principal business is investing in the equities of public micro-cap issuers. Located at 19605 N.E. 8th St., Camas, Washington 98607. No convictions or administrative proceedings as described in 2 (d) and (e).

Item 3. Source and Amount of Funds or Other Consideration.

Source of funds is money invested in the partnership by its partners.

Item 4. Purpose of Transaction.

We continue to be pleased with BABY's progress, so much so that we anticipate purchasing more shares right up to the poison pill limit of 15%, subject, of course, to price and availability.

BABY has strengthened corporate governance with the addition of three new outside directors and the election of a new independent board Chair, Bob Gunst. We have worked closely with Bob before, when he served as board chair at Garden Fresh Restaurant (LTUS), where he did an excellent job of building, and of harvesting, shareholder value.

Also, we are pleased with the actions Jim Hawkins already has taken during his first several months as BABY's new CEO. Not only is he cost-reducing the company to immediate profitability and flattening its previously top heavy management structure, more importantly, he is taking the steps needed to reinvigorate growth in BABY's core hearing screening business. The just-announced acquisition of the Fischer-Zoth company is far more significant than its current size: it should enable BABY to accelerate penetration of foreign country markets which prefer the OAE modality; it could build audiologist support for BABY; it brings strong technology capability to BABY's R&D department; and it opens up the adjacent market segment of office-based pediatrician

screening of children. At his prior company Jim Hawkins did a terrific job of building synergistic, profitable growth through acquisitions. With Fischer-Zoth he is doing the same thing here at BABY.

- Item 5. Interest in Securities of the Issuer.
 - (a,b) D3 Family Bulldog Fund, L.P. owns and has sole voting power over 268,233 BABY shares.
 - (c) N/A
 - (d) N/A
 - (e) N/A
- Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

N/A

Item 7. Material to be Filed as Exhibits.

N/A

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sept. 29, 2004

Date

David Nierenberg

President

Nierenberg Investment Management

Company, Inc., the General Partner

of The D3 Family Bulldog Fund, L.P.

Item 1. Security and Issuer.

Common Stock of Natus Medical Incorporated, 1501 Industrial Road, San Carlos, CA 94070

Item 2. Identity and Background.

Henry Hooper. Located at 4317 NE Wistaria Drive, Portland, Oregon 97213. Mr. Hooper is a general partner of the D3 Family Fund, L.P. No convictions or administrative proceedings as described in 2 (d) and (e).

Item 3. Source and Amount of Funds or Other Consideration.

Source of funds is money invested in the partnership by its partners.

Item 4. Purpose of Transaction.

The purchase of the shares is for investment purposes.

Item 5. Interest in Securities of the Issuer.

- (a,b) Henry Hooper owns and has sole voting power over 1,500 BABY shares.
- (c) N/A
- (d) N/A
- (e) N/A
- Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

N/A

Item 7. Material to be Filed as Exhibits.

N/A

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sept. 29, 2004 -----Date /s/ DAVID NIERENBERG

David Nierenberg President

> Nierenberg Investment Management Company, Inc., Authorized to trade for Henry Hooper